Literature DB >> 15187522

Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats.

Ivo G Schoots1, Marcel Levi, Arlène K van Vliet, Adrie M Maas, E H Paulina Roossink, Thomas M van Gulik.   

Abstract

OBJECTIVE: To examine whether administration of activated protein C or antithrombin reduces local splanchnic derangement of coagulation and inflammation and attenuates intestinal dysfunction and injury following intestinal ischemia/reperfusion.
DESIGN: Randomized prospective animal study.
SETTING: University research institute.
SUBJECTS: Adult male Wistar rats, weighing 300-325 g (n = 72).
INTERVENTIONS: Rats were subjected to superior mesenteric artery occlusion consisting of 20 or 40 mins of ischemia and 3 hrs of reperfusion. A randomized intravenous administration of vehicle (0.9% NaCl), heparin, antithrombin, or activated protein C was performed during ischemia, 15 mins before reperfusion. Coagulation and fibrinolysis variables obtained from portal blood were correlated with mucosal fibrin deposition (determined by anti-rat fibrin antibody staining), intestinal function (glucose/water clearance), and intestinal injury (histologic evaluation by Park/Chiu score).
MEASUREMENTS AND MAIN RESULTS: Activated protein C- or antithrombin-treated animals demonstrated less ischemia/reperfusion-induced intestinal dysfunction and histologic changes compared with control animals, whereas intravenous administration of heparin only showed less histologic derangement. Activated protein C- or antithrombin-treated animals showed less thrombin generation, fibrin degradation products, and fibrin deposition compared with control animals, as confirmed by histologic examination, whereas heparin administration showed only a limited reduction of portal fibrin degradation product concentrations. Furthermore, activated protein C or antithrombin administration markedly inhibited the inflammatory response, as reflected by reduced interleukin-6 plasma concentrations to baseline values, whereas heparin had no effect.
CONCLUSIONS: Administration of activated protein C or antithrombin inhibited local and systemic derangement of coagulation and inflammation following intestinal ischemia/reperfusion, diminished mucosal fibrin deposition, and attenuated ischemia/reperfusion-induced intestinal injury. These observations suggest that activated protein C or antithrombin reduces ischemia/reperfusion-induced intestinal injury, both through their anticoagulant and anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187522     DOI: 10.1097/01.ccm.0000128567.57761.e9

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  17 in total

1.  Ketamine reduces intestinal injury and inflammatory cell infiltration after ischemia/reperfusion in rats.

Authors:  Francisco Javier Guzmán-De La Garza; Carlos Rodrigo Cámara-Lemarroy; Raquel Guadalupe Ballesteros-Elizondo; Gabriela Alarcón-Galván; Paula Cordero-Pérez; Nancy Esthela Fernández-Garza
Journal:  Surg Today       Date:  2010-11-03       Impact factor: 2.549

2.  Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.

Authors:  Jason D Christie; Nancy Robinson; Lorraine B Ware; Michael Plotnick; Joao De Andrade; Vibha Lama; Aaron Milstone; Jonathan Orens; Ann Weinacker; Ejigayehu Demissie; Scarlett Bellamy; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2006-10-05       Impact factor: 21.405

3.  Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury.

Authors:  Yina Ma; Jinli Wang; Junjie Gao; Hui Yang; Yanqing Wang; Chandrashekhara Manithody; Ji Li; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

4.  Role of activated protein C on wound healing process in left colonic anastomoses in the presence of intra-abdominal sepsis induced by cecal ligation and puncture: an experimental study in the rat.

Authors:  Zafer Teke; Suzan Sacar; Cigdem Yenisey; A Ozgur Atalay; Tulay Kavak; Ergun Erdem
Journal:  World J Surg       Date:  2008-08-05       Impact factor: 3.352

5.  Ketamine and the myenteric plexus in intestinal ischemia/reperfusion injury.

Authors:  Francisco Javier Guzmán-de la Garza; Carlos Rodrigo Cámara-Lemarroy; Raquel Guadalupe Ballesteros-Elizondo; Gabriela Alarcón-Galván; Paula Cordero-Pérez; Nancy Esthela Fernández-Garza
Journal:  Dig Dis Sci       Date:  2009-09-16       Impact factor: 3.199

6.  Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats.

Authors:  Francisco Javier Guzmán-de la Garza; Carlos Rodrigo Cámara-Lemarroy; Gabriela Alarcón-Galván; Paula Cordero-Pérez; Linda Elsa Muñoz-Espinosa; Nancy Esthela Fernández-Garza
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

7.  Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease.

Authors:  Franco Scaldaferri; Miquel Sans; Stefania Vetrano; Cristina Graziani; Raimondo De Cristofaro; Bruce Gerlitz; Alessandro Repici; Vincenzo Arena; Alberto Malesci; Julian Panes; Brian W Grinnell; Silvio Danese
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

8.  Intestinal ischemia-reperfusion injury alters purinergic receptor expression in clinically relevant extraintestinal organs.

Authors:  Peter M Milano; Christelle D Douillet; Paul J Riesenman; William P Robinson; Stephanie K Beidler; Ben L Zarzaur; Preston B Rich
Journal:  J Surg Res       Date:  2007-08-03       Impact factor: 2.192

Review 9.  [Mechanisms of action of recombinant human activated Protein C].

Authors:  M Brueckmann; G Huhle; M Max
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

10.  Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.

Authors:  Jorrit J Hofstra; Alexander D Cornet; Bart F de Rooy; Alexander P Vlaar; Tom van der Poll; Marcel Levi; Sebastian Aj Zaat; Marcus J Schultz
Journal:  Crit Care       Date:  2009-09-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.